Meeting
2022 ASCO Annual Meeting
Cost-effectiveness of adjuvant chemotherapy for patients with high-risk stage II and stage III colon cancer in South Africa.
Authors
Yoanna S Pumpalova
Columbia University Irving Medical Center, New York, NY
Yoanna S Pumpalova , Alexandra M. Rogers , Sarah Xinhui Tan , Candice-Lee Herbst , Paul Ruff , Alfred I. Neugut , Chin Hur
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Health Services Research and Quality Improvement
Track
Quality Care/Health Services Research
Sub Track
Value/Cost of Care
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 6599)
DOI
10.1200/JCO.2022.40.16_suppl.6599
Abstract #
6599
Poster Bd #
380
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
Survival and patient-reported outcomes of real-world patients with high-risk stage II and stage III colon cancer after 3 versus 6 months of adjuvant CAPOX.
First Author: Ingrid A. Franken
Poster
2020 Gastrointestinal Cancers Symposium
The influence of adjuvant chemotherapy dose intensity on overall survival in resected colon cancer: A multicenter retrospective analysis.
First Author: Suganija Lakkunarajah
Poster
2018 Gastrointestinal Cancers Symposium
Clinical impact of diverting ileostomy on the dose intensity of adjuvant chemotherapy for colorectal cancer.
First Author: Shusuke Yagi
Poster
2013 Gastrointestinal Cancers Symposium
Effectiveness of capecitabine plus oxaliplatin for advanced colon cancer: A public hospital experience.
First Author: Carrie Luu